Started from late last year, the massive shift in South Korean market sales rights over global vaccines has come to an end. Global companies like MSD, GSK and Sanofi Pasteur, and South Korean companies like GC Pharma, SK Bioscience, HK inno.N, Yuhan Corporation and Handok were involved in the mass migration of the businesses.

The industry sees that HK inno.N took the biggest piece of the pie during the process. SK Bioscience letting go of one deal and taking another was also evaluated to have defended its position successfully. Also Handok was able to maintain its deals.

However, GC Pharma and Yuhan are to minimize their loss of losing existing deals by concentrating on other items.